Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q2 FY24 results · Jul–Sep 2023
Alivus Life Sciences reported revenue from operations of ₹595.36 crore (up 16.9% from Q2 FY23) and net profit of ₹118.74 crore (up 11.1% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a standalone basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 595.36 | 509.30 | +16.9% | 578.45 | +2.9% |
| Other income | 5.37 | 10.02 | −46.4% | 1.85 | +190.1% |
| Total income | 600.73 | 519.32 | +15.7% | 580.30 | +3.5% |
| Profit before tax | 158.93 | 143.59 | +10.7% | 182.00 | −12.7% |
| Net profit for the period | 118.74 | 106.88 | +11.1% | 135.45 | −12.3% |
| EPS, basic (₹) | 9.69 | 8.72 | +11.1% | 11.05 | −12.3% |
| Net margin (%) | 19.9 | 21.0 | 23.4 |
Standalone
- Filed with BSE
- 31 Oct 2023, 15:40 IST
- Board meeting
- 20 Oct 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE